MedTrace Logo

Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

NCT00608465 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-08-11

Study results available
· View outcomes & findings →

Summary

The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.

Conditions

  • Metabolic Syndrome X

Interventions

DRUG

Eplerenone

5 mg x 1 week followed by 10 mg x 9 weeks.

DRUG

Ramipril

Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • James AS Muldowney, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608465 on ClinicalTrials.gov